Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis
- 1 January 2021
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 160 (1), 88-98.e4
- https://doi.org/10.1053/j.gastro.2020.09.041
Abstract
No abstract availableFunding Information
- Boehringer Ingelheim
- Gilead Sciences
- Allergan
This publication has 44 references indexed in Scilit:
- American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel SyndromeGastroenterology, 2014
- Partner Burden in Irritable Bowel SyndromeClinical Gastroenterology and Hepatology, 2013
- Burden of Gastrointestinal Disease in the United States: 2012 UpdateGastroenterology, 2012
- Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysisClinical Gastroenterology and Hepatology, 2012
- Increasing Frequency of Opioid Prescriptions for Chronic Abdominal Pain in US Outpatient ClinicsClinical Gastroenterology and Hepatology, 2011
- Biopsychosocial Model of Irritable Bowel SyndromeJournal of Neurogastroenterology and Motility, 2011
- Prescribing Patterns for the Outpatient Treatment of Constipation in the United StatesDigestive Diseases and Sciences, 2010
- Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validationPharmacoepidemiology and Drug Safety, 2005
- Definition and epidemiology of functional gastrointestinal disordersBest Practice & Research Clinical Gastroenterology, 2004
- The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjectsAlimentary Pharmacology & Therapeutics, 2003